-
TRUSTED AU LABORATORY
-
26 Mark Rd. Elizabeth South, SA - 5112
-
Same day delivery
Pull the syringe to:
(0.100ml)
This calculator is provided as a reference tool for research purposes only. Always follow your institution’s safety protocols when handling research compounds.
PT-141 10mg is a synthetic research peptide studied in relation to melanocortin receptor pathway research, bremelanotide research, neuroendocrine signalling models, MC receptor biology and central nervous system pathway studies.
PT-141 is commonly known as bremelanotide. PubChem lists bremelanotide with the molecular formula C50H68N14O10. DailyMed describes VYLEESI as a regulated bremelanotide injection product containing bremelanotide, a melanocortin receptor agonist.
This product is supplied for laboratory research use only. It is not a medicine, supplement, sexual wellness product, libido product, erectile function product, hormone product, performance product or injectable product for human use.
| Product Detail | Information |
|---|---|
| Product name | PT-141 |
| Common research name | Bremelanotide |
| Size | 10mg |
| Product type | Research peptide |
| Research category | Melanocortin Research / Neuropeptide Research |
| Common research interest | Melanocortin receptor signalling, neuroendocrine pathway research and central nervous system pathway models |
| Peptide type | Synthetic cyclic heptapeptide |
| Main receptor interest | Melanocortin receptors |
| Molecular formula | C50H68N14O10 |
| Form | Lyophilised powder |
| Intended use | Laboratory research only |
| Human use | Not for human consumption, administration, libido, sexual function, performance or injection |
| Documentation | Certificate of Analysis should be checked before use |
| Component | Research Class | General Research Role |
| PT-141 | Synthetic research peptide | Studied in melanocortin receptor and neuroendocrine pathway research |
| Bremelanotide | Common pharmacological and research name | Used in scientific and regulated medicine literature |
| Cyclic heptapeptide structure | Modified peptide structure | Studied for melanocortin receptor pathway interaction |
| Melanocortin receptor activity | Receptor pathway research | Relevant to MC receptor signalling models |
| Molecular formula | C50H68N14O10 | Listed by PubChem for bremelanotide |
| Bremelanotide acetate | Regulated medicine salt/form context | Appears in approved medicine documentation and should not be assumed for research vials |
| Lyophilised peptide preparation | Freeze-dried peptide format | Supports stability before reconstitution when stored correctly |
Product identity, sequence, salt form, purity, acetate status and batch information should always be confirmed through supplier documentation and the Certificate of Analysis. Researchers should not rely on the product name alone when confirming peptide identity.
PT-141 is studied as a melanocortin receptor pathway research peptide. In research settings, melanocortin-related compounds are examined for how they interact with melanocortin receptor subtypes and influence neuroendocrine signalling, central nervous system pathways and behavioural research models.
DailyMed describes bremelanotide as a melanocortin receptor agonist that nonselectively activates several melanocortin receptor subtypes, with activity discussed across MC1R, MC4R, MC3R, MC5R and MC2R. This is regulated medicine and pharmacology context only, not a product-use claim for a research vial.
PT-141 is often discussed online in relation to libido, sexual function and performance. That consumer framing is not suitable for a research-use product page. This page should focus on melanocortin receptor pathway research only.
| Research Area | PT-141 |
| Main research category | Melanocortin receptor research |
| Common name | Bremelanotide |
| Peptide structure | Synthetic cyclic heptapeptide |
| Common pathway interest | Melanocortin receptor signalling |
| Receptor interest | MC receptor subtype pathway models |
| Neuroendocrine interest | Central nervous system and behavioural pathway research |
| Clinical medicine context | Regulated bremelanotide medicines exist overseas, but are not equivalent to research vials |
| Evidence limitation | Human medicine context must not be used as a claim for research products |
| Product limitation | Research use only, not approved for human use |
| Feature | PT-141 | Melanotan II |
| Common research name | Bremelanotide | Melanotan II |
| Research class | Melanocortin receptor research peptide | Melanocortin receptor research peptide |
| Main research interest | Neuroendocrine and melanocortin receptor pathway research | Melanocortin, pigmentation and receptor pathway research |
| Common online claim risk | Libido, sexual function and performance claims | Tanning, pigmentation and sexual function claims |
| Safer positioning | Bremelanotide melanocortin pathway research | Melanocortin and pigmentation pathway research |
| Human-use claim | Not appropriate for research-use products | Not appropriate for research-use products |
| Feature | PT-141 | Melanotan I |
| Common research name | Bremelanotide | Afamelanotide-related melanocortin analogue |
| Research class | Melanocortin receptor research peptide | Melanocortin receptor research peptide |
| Common pathway interest | MC receptor and neuroendocrine pathway models | MC1R, pigmentation and photobiology pathway research |
| Common SEO risk | Sexual wellness and libido claims | Tanning and skin-darkening claims |
| Safer positioning | Melanocortin receptor pathway research | Melanocortin and pigmentation pathway research |
| Human-use claim | Not appropriate | Not appropriate |
| Feature | PT-141 | Kisspeptin |
| Research class | Melanocortin receptor research peptide | Reproductive axis neuropeptide research |
| Main receptor/pathway | Melanocortin receptor pathway | Kisspeptin receptor / GnRH axis pathway |
| Common research interest | Neuroendocrine and behavioural pathway models | Reproductive hormone signalling and GnRH pathway research |
| Common SEO risk | Libido and sexual performance claims | Fertility and hormone claims |
| Safer positioning | Melanocortin receptor research peptide | Reproductive axis research peptide |
| Human-use claim | Not appropriate | Not appropriate |
| Product | Safer Research Positioning |
| PT-141 10mg | Bremelanotide and melanocortin receptor pathway research |
| Melanotan I 10mg | Melanocortin and pigmentation pathway research |
| Melanotan II 10mg | Melanocortin receptor pathway and pigmentation research |
| Kisspeptin research products | Reproductive axis and GnRH pathway research |
These products should not be written as if they are interchangeable. PT-141 is best positioned around bremelanotide and melanocortin receptor pathway research, not tanning, libido, erectile function or sexual performance use.
| Common Online Claim | Safer Research-Use Wording |
| Libido | Studied in melanocortin receptor and neuroendocrine pathway research models |
| Sexual function | Better framed as behavioural and neuroendocrine pathway research |
| Arousal | Better framed as central nervous system pathway research |
| Erectile function | Not an approved or appropriate claim for research-use material |
| Female sexual desire | Only relevant to approved regulated medicines, not research vials |
| Performance enhancement | Not an approved or appropriate product claim |
| Hormone support | Better framed as neuroendocrine pathway research |
| Relationship or wellness use | Not suitable for research-use product positioning |
PT-141 10mg is not intended to diagnose, treat, cure or prevent any disease. It is not supplied for libido, sexual function, sexual desire, erectile function, arousal, relationship wellness, fertility, hormone support, performance enhancement, bodybuilding, anti-ageing, mood, confidence or general wellness use.
All information on this page is provided for laboratory research and product handling context only.
There is no universal recommended dilution for PT-141 10mg. Dilution depends on the research protocol, required working concentration, assay design, solvent compatibility, salt form, storage method and validated laboratory procedure.
For research concentration planning only, the basic formula is:
Total peptide amount divided by diluent volume equals final concentration.
| Diluent Added to 10mg Vial | Final Concentration |
| 1mL | 10mg/mL |
| 2mL | 5mg/mL |
| 2.5mL | 4mg/mL |
| 3mL | 3.33mg/mL |
| 4mL | 2.5mg/mL |
| 5mL | 2mg/mL |
| 10mL | 1mg/mL |
These are research concentration examples only. They are not human dosing instructions and must not be used to calculate injection quantities.
Before handling PT-141 10mg in a laboratory setting, make sure all materials, documentation and clean handling conditions are prepared.
| Item | Purpose |
| Product vial | Contains lyophilised PT-141 peptide |
| Certificate of Analysis | Confirms batch-level testing information |
| Sequence or identity confirmation | Helps confirm the product is PT-141 / bremelanotide |
| Suitable research-grade diluent | Used to prepare a working research solution |
| Sterile lab consumables | Helps reduce contamination risk |
| Personal protective equipment | Gloves, lab coat and eye protection |
| Alcohol wipes or approved disinfectant | Used for surface and vial-top preparation |
| Laboratory labels | Records concentration, date, batch and handler details |
| Cold storage access | Supports correct storage after preparation |
| Disposal container | Used for compliant laboratory waste disposal |
The following is a general laboratory handling framework only. Always follow the product Certificate of Analysis, supplier documentation, SDS, institutional procedures and validated research protocol.
Check the product label, batch number, Certificate of Analysis, peptide identity and storage requirements before handling the vial.
Use a clean laboratory workspace. Wear appropriate PPE and disinfect the bench surface, vial top and any required equipment.
If the vial has been stored cold, allow it to equilibrate according to laboratory procedure before opening or reconstitution. Avoid condensation entering the vial.
Add the selected research-grade diluent slowly down the inside wall of the vial. Avoid forceful spraying directly onto the lyophilised powder.
Gently swirl or roll the vial until the powder is dissolved. Avoid aggressive shaking, unnecessary vortexing or foaming unless a validated protocol specifically allows it.
Check the solution for cloudiness, visible particles, unusual colour changes or undissolved material. If anything appears abnormal, quarantine the vial and check supplier documentation.
Label the vial or aliquots with the product name, concentration, diluent used, date prepared, batch number and researcher initials.
Place the reconstituted solution into the required storage condition as soon as possible. Avoid unnecessary warming, cooling or repeated freeze-thaw cycles.
Some lyophilised peptide products may take time to fully hydrate. Dissolution should always be handled gently and according to laboratory protocol.
| Issue | What It May Indicate | Safer Response |
| Powder clinging to vial wall | Static or lyophilisation residue | Allow more contact time with diluent |
| Small particles remain | Incomplete hydration | Continue gentle swirling |
| Cloudy solution | Possible incompatibility or contamination | Stop and check documentation |
| Foaming | Too much agitation | Let the solution settle and avoid shaking |
| Colour change | Possible degradation or contamination | Do not continue without supplier guidance |
| Product identity unclear | Possible peptide mix-up | Stop and confirm CoA before using |
| Storage Factor | Guidance |
| Product form | Lyophilised powder |
| Storage condition | Follow supplier label and Certificate of Analysis |
| Light exposure | Protect from unnecessary light exposure |
| Moisture exposure | Keep sealed until use |
| Temperature changes | Avoid repeated temperature cycling |
| Handling | Minimise unnecessary opening or vial puncture |
| Variant control | Store and label separately from Melanotan I, Melanotan II and other melanocortin products |
| Storage Factor | Guidance |
| Storage condition | Follow validated research protocol |
| Labelling | Record product name, concentration, date, diluent and batch number |
| Freeze-thaw cycles | Avoid repeated freeze-thaw exposure |
| Aliquoting | Use small research aliquots where appropriate |
| Contamination control | Use clean laboratory technique |
| Light exposure | Protect from unnecessary light exposure where required |
| Disposal | Dispose according to laboratory waste procedures |
Peptides may be sensitive to temperature, light, pH, agitation and contamination. Storage conditions should be confirmed through supplier documentation or the laboratory’s validated method.
This page does not provide human dosing, injection instructions, injection schedules or administration guidance.
PT-141 10mg is not supplied for human or animal administration. It is a laboratory research-use product only.
Regulated bremelanotide medicines have product-specific prescribing information, formulation-specific administration instructions, sponsor-controlled quality systems and approved indications. Those instructions are not transferable to research-use peptide vials, different strengths, different suppliers or non-approved products.
For research settings, any measured aliquots should be prepared according to the concentration required by the approved research protocol. All calculations should be checked, documented and traceable.
| Planning Item | What to Record |
| Final concentration | Total peptide amount and diluent volume |
| Working solution | Concentration used in the research protocol |
| Aliquot volume | Volume transferred into each labelled lab tube |
| Batch details | Product batch, CoA and preparation date |
| Peptide identity | Confirmation that the product is PT-141 / bremelanotide |
| Salt form | Acetate or supplier-specific salt form, where documented |
| Storage location | Fridge, freezer or other controlled storage area |
| Handler details | Researcher name or initials |
| Preparation date | Date and time of reconstitution |
| Disposal date | When the aliquot should no longer be used |
| Strength check | Confirmation that the 10mg vial strength matches the approved research protocol |
Correct handling is important for research consistency, contamination control and product traceability. Most mistakes occur when products are not labelled clearly, concentration calculations are not recorded, storage conditions are not followed or regulated medicine information is copied into a research-use product page.
Because PT-141 is commonly discussed online in relation to libido, sexual function and performance, product pages should avoid wording that could be interpreted as encouraging human self-use, injection, sexual wellness use or treatment use.
| Always | Why It Matters |
| Check the Certificate of Analysis | Confirms batch-level information |
| Confirm peptide identity | Helps verify the product is PT-141 / bremelanotide |
| Confirm salt form where documented | Supports correct research calculations |
| Use PPE | Reduces contamination and exposure risk |
| Label every vial and aliquot | Prevents mix-ups |
| Record concentration calculations | Supports traceability |
| Use clean laboratory technique | Reduces contamination risk |
| Follow institutional protocols | Keeps handling consistent and auditable |
| Store according to documentation | Helps protect peptide integrity |
| Dispose of lab waste correctly | Supports safety and compliance |
| Use research-use wording only | Reduces misleading human-use interpretation |
| Clearly separate research pathways from human benefit claims | Avoids unsafe or misleading product positioning |
| Never | Why It Is Risky |
| Never use for self-injection | Product is research use only |
| Never sell or promote as a libido product | Creates human-use and compliance risk |
| Never make sexual function or arousal claims | Not an approved or appropriate product claim |
| Never make erectile function claims | Not suitable for a research-use product page |
| Never describe it as a sexual performance enhancer | Misleading and not appropriate |
| Never market as a relationship or wellness product | Creates misleading human-use interpretation |
| Never imply equivalence to VYLEESI | Regulated medicine context is product-specific |
| Never copy dosing from approved medicine labels | Formulations, strengths and approved contexts differ |
| Never assume purity without CoA | Batch quality must be documented |
| Never use a damaged or unlabelled vial | Identity and sterility may be uncertain |
| Never shake aggressively | May affect peptide integrity |
| Never use random solvents | May damage the peptide or alter research results |
| Never leave reconstituted product unlabelled | Creates traceability risk |
| Never rely on social media protocols | They may be inaccurate, unsafe or non-compliant |
The table below is for concentration planning only. It does not represent dosage, injection quantity or recommended administration.
| Total Vial Amount | Diluent Volume | Final Concentration |
| 10mg | 1mL | 10mg/mL |
| 10mg | 2mL | 5mg/mL |
| 10mg | 2.5mL | 4mg/mL |
| 10mg | 3mL | 3.33mg/mL |
| 10mg | 4mL | 2.5mg/mL |
| 10mg | 5mL | 2mg/mL |
| 10mg | 10mL | 1mg/mL |
If a researcher adds 2mL of suitable research-grade diluent to a 10mg vial, the resulting concentration is 5mg/mL.
This calculation is for research concentration planning only. It is not a human or animal dosing example.
PT-141 is a synthetic research peptide commonly known as bremelanotide. It is studied in relation to melanocortin receptor signalling, neuroendocrine pathway research and central nervous system pathway models.
Yes. PT-141 is commonly known as bremelanotide in research and regulated medicine literature. PubChem lists bremelanotide with the molecular formula C50H68N14O10.
PT-141 is commonly studied in relation to melanocortin receptor signalling. DailyMed describes bremelanotide as a melanocortin receptor agonist, although that pharmacology information relates to a regulated medicine context and should not be used as a product-use claim for research material.
This research product is not approved or supplied for libido, sexual function, arousal, erectile function, sexual wellness, relationship wellness or human administration. It should be described only as a laboratory research product.
No. PT-141 and Melanotan II are both discussed in melanocortin receptor research contexts, but they are different research products with different positioning. PT-141 is best positioned around bremelanotide and melanocortin receptor pathway research, while Melanotan II is commonly positioned around melanocortin and pigmentation pathway research.
No. PT-141 is commonly known as bremelanotide and is positioned around melanocortin receptor pathway research. Melanotan I is positioned around melanocortin and pigmentation pathway research.
VYLEESI is a regulated bremelanotide medicine with product-specific prescribing information, formulation and approved indication. A research-use PT-141 10mg vial is not equivalent to that regulated medicine.
A Certificate of Analysis provides batch-level testing information. It helps researchers verify product identity, purity, salt form, sequence and quality documentation before use in a research setting.
| Resource | Why It Is Useful |
| PubChem Bremelanotide compound profile | Useful background on PT-141 / bremelanotide identity and molecular formula. |
| DailyMed VYLEESI bremelanotide label | Useful context showing regulated bremelanotide medicine information is formulation-specific and not transferable to research vials. |
PT-141 10mg for qualified laboratory research only. Not for human or veterinary use.
